methyl-CpG binding domain protein 3 like 2BGenealiases: []
Q-omics provides the consensus-scored MBD3L2B profile across patient tissues and cancer cell-line models. MBD3L2B expression is associated with patient survival in 10 of 34 cancer types, with the highest sampling consensus in CESC. Among the 18 cancer types available for tumor–normal comparison, MBD3L2B is differentially expressed in 2, with the highest sampling consensus in KIRP. Additionally, MBD3L2B RNA expression shows 8,246 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight CESC, KIRP, and TGCT as cancer lineages where MBD3L2B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MBD3L2B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MBD3L2B survival associations across molecular data types. MBD3L2B RNA expression shows survival associations in the most cancer types (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MBD3L2B RNA expression–survival associations across cancer types. High MBD3L2B expression shows unfavorable associations in CESC, LIHC, ACC, DLBC, UCEC and ESCA. The CESC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify CESC as the clearest survival context for MBD3L2B RNA expression.
This table summarizes MBD3L2B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for MBD3L2B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MBD3L2B shows higher tumor expression in KIRP and KIRC. The KIRP box plot shows higher MBD3L2B RNA expression in tumor versus normal tissue (log2 FC = +0.022, t-test p = .037).
This table shows molecular features associated with MBD3L2B in patient tissues and cancer cell lines. In patient samples, MBD3L2B shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, MBD3L2B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and SKIN.
